Indeed, we found patients with sarcoma with TP53 mutations have higher PRL2 mRNA expression and lower PTEN protein level, supporting our hypothesis that targeting PRL2 to enhance PTEN level could serve as a therapeutic approach for cancer treatment in TP53-driven cancer. This evidence concerns the gene TP53 and sarcoma.